The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon‐Aminocaproic Acid to Reduce Bleeding in TKA : A Systematic Review and Bayesian Network Meta‐analysis
Orthopaedic Surgery · 2023
DOI: 10.1111/os.13678 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Orthopaedic Surgery, 2023. Verfasst von Che Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Aminocaproic Acid, Antifibrinolytic Agents, Arthroplasty, Replacement, Knee, Tranexamic Acid. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Science and Technology of Sichuan Province, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University.
Abstract (Originalsprache)
Objective
The optimal dose and efficacy of tranexamic acid (TXA) and epsilon‐aminocaproic acid (EACA) in total knee arthroplasty (TKA) were under controversial, and we aimed to make comparisons between different doses of TXA and EACA in intravenous (IV) or intra‐articular (IA) applications in patients undergoing TKA.
Methods
This network meta‐analysis was guided by the Priority Reporting Initiative for Systematic Assessment and Meta‐Analysis (PRISMA). According to the administrations of antifibrinolytic agents, patients in eligible studies were divided into three subgroups: (i) IA applications of TXA and EACA; (ii) IV applications (g) of TXA and EACA; (iii) IV applications (mg/kg) of TXA and EACA. Total blood loss (TBL), hemoglobin (HB) drops and transfusion rates were the primary outcomes, while drainage volume, pulmonary embolism (PE) or deep vein thrombosis (DVT) risk were the secondary outcomes. A multivariate Bayesian random‐effects model was adopted in the network analysis.
Results
A total of 38 eligible trials with different regimens were assessed. Overall inconsistency and heterogeneity were acceptable. Taking all primary outcomes into account, 1.0–3.0 g TXA were most effective in IA applications, 1–6 g TXA and 10–14 g EACA were most effective in IV applications (g), while 30 mg/kg TXA and 150 mg/kg EACA were most effective in IV applications (mg/kg). None of the regimens showed increasing risk for pulmonary embolism (PE) or deep vein thrombosis (DVT) compared with placebo.
Conclusion
0 g IA TXA , 1.0 g IV TXA or 10.0 g IV EACA , as well as 30 mg/kg IV TXA or 150 mg/kg IV EACA were most effective and enough to control bleeding for patients after TKA . TXA was at least 5 times more potent than EACA .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Bin Shen
Förderung
- Department of Science and Technology of Sichuan Province
- National Clinical Research Center for Geriatrics, West China Hospital Sichuan University
Zitieren
APA
Zheng, C., Ma, J., Xu, J., Li, M., Wu, L., Wu, Y., Liu, Y., & Shen, B. (2023). The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon‐Aminocaproic Acid to Reduce Bleeding in TKA : A Systematic Review and Bayesian Network Meta‐analysis. Orthopaedic Surgery. https://doi.org/10.1111/os.13678
Vancouver
Zheng C, Ma J, Xu J, Li M, Wu L, Wu Y, et al. The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon‐Aminocaproic Acid to Reduce Bleeding in TKA : A Systematic Review and Bayesian Network Meta‐analysis. Orthopaedic Surgery. 2023. doi:10.1111/os.13678
BibTeX
@article{Zheng2023,
author = {Zheng, Che and Ma, Jun and Xu, Jiawen and Li, Mingyang and Wu, Liming and Wu, Yuangang and Liu, Yuan and Shen, Bin},
title = {The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon‐Aminocaproic Acid to Reduce Bleeding in TKA : A Systematic Review and Bayesian Network Meta‐analysis},
journal = {Orthopaedic Surgery},
year = {2023},
doi = {10.1111/os.13678}
}
EUVIMED